Magazine Article | October 2, 2023

Key Takeaways From The FDA Guidance On DCTs

Source: Life Science Leader

By Atul Gupta and Akash Gadgade

In recent years, there has been a significant increase in the adoption of decentralized trials (DCTs), largely catalyzed by the COVID-19 pandemic. The U.S. FDA defines DCTs as trials in which trial-related activities occur at locations beyond traditional sites. According to a study published in Forbes, the degree of decentralization in clinical trials prior to the pandemic was approximately 43%. However, by the year 2022, this figure had risen to 55%.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader